-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The ability of curto-pearl monoantigen, pato-pearl monoantigen and T-DM1 significantly improved the survival prognostic period of advanced HER2-positive breast cancer.
, metastasis HER2-positive breast cancer is still a powerful tumor.
, new treatment strategies and molecular biomarkers need to be explored to further improve patient prognostics.
PATRICIA study is a forward-looking, open-label, multi-center Phase II trial designed to assess the efficacy and safety of Palbociclib-co-or-not-combination endocrine therapy in patients with HER2-positive advanced breast cancer.
the study was based on Simon's two-stage design and divided into three queues: queue A: estrogen-positive (ER) negative; queue B:ER-positive; and queue C:ER-positive-infested.
ER-positive patients were further asseded to queue B1 or queue B2.
Pabosini drug program: 200mg/day, suspended for two weeks for one week.
end point is a progress-free survival rate (PFS6) at 6 months.
secondary endpoints include safety and assessment of the paM50 in-house subsype.
recruited a total of 71 patients (15, 28 and 28 in the three groups A, B and C, respectively).
PFS6 for queues A, B1 and B2 were 33.3% (5/15), 42.8% (12/28) and 46.4% (13/28), respectively.
1-2 and 3-4 toxic reactions occurred in 97.7% and 84.4% of patients, respectively.
most common level 3-4 toxicity reactions were neutral granulocyte reduction (66.4%) and plate small plate reduction (11.3%).
as for PAM50, 59 cases (83.1%) of tumors were analyzed.
compared to non-tube cavity type, it was found that tube cavity breast cancer defined by PAM50 was independently associated with longer PFS (medium PFS: 10.6 vs 4.2 months, p=0.003).
Pabosini is safe to use in combined with curtoju monoantigen, and a better survival prognosticity is shown in terracial A or B sub-type ER-positive/HER2-positive advanced breast cancer.
a new randomized trial in the patient group that stopped recruiting patients early.
